[
    {
        "id": 3875,
        "drug_name": "ASCENIV (RI-002)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Primary Immune Deficiency Diseases",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-13",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ADMA\/news\/104771",
        "note": "FDA supplemental approval for room temperature (25\u00b0C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life.",
        "company_entity_id": 14,
        "company_ticker": "ADMA",
        "company_name": "ADMA Biologics Inc",
        "company_price": "6.2200",
        "company_change": 0.04,
        "company_percent_change": 0.65,
        "company_optionable": 1,
        "company_number_of_shares": 228220236,
        "price_change_sparkline": [
            [
                5.19,
                1706677200
            ],
            [
                5.3,
                1706763600
            ],
            [
                5.23,
                1706850000
            ],
            [
                5.18,
                1707109200
            ],
            [
                5.27,
                1707195600
            ],
            [
                5.18,
                1707282000
            ],
            [
                5.17,
                1707368400
            ],
            [
                5.24,
                1707454800
            ],
            [
                5.46,
                1707714000
            ],
            [
                5.17,
                1707800400
            ],
            [
                5.33,
                1707886800
            ],
            [
                5.4,
                1707973200
            ],
            [
                5.28,
                1708059600
            ],
            [
                5.15,
                1708405200
            ],
            [
                5.18,
                1708491600
            ],
            [
                5.26,
                1708578000
            ],
            [
                5.26,
                1708664400
            ],
            [
                5.4,
                1708923600
            ],
            [
                5.52,
                1709010000
            ],
            [
                5.38,
                1709096400
            ],
            [
                5.36,
                1709182800
            ],
            [
                5.52,
                1709269200
            ],
            [
                5.72,
                1709528400
            ],
            [
                5.8,
                1709614800
            ],
            [
                6.12,
                1709701200
            ],
            [
                6.16,
                1709787600
            ],
            [
                6.34,
                1709874000
            ],
            [
                6.18,
                1710129600
            ],
            [
                6.22,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5041,
        "drug_name": "BIVIGAM",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Primary humoral immunodeficiency",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-13",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ADMA\/news\/104771",
        "note": "FDA supplemental approval for room temperature (25\u00b0C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life.",
        "company_entity_id": 14,
        "company_ticker": "ADMA",
        "company_name": "ADMA Biologics Inc",
        "company_price": "6.2200",
        "company_change": 0.04,
        "company_percent_change": 0.65,
        "company_optionable": 1,
        "company_number_of_shares": 228220236,
        "price_change_sparkline": [
            [
                5.19,
                1706677200
            ],
            [
                5.3,
                1706763600
            ],
            [
                5.23,
                1706850000
            ],
            [
                5.18,
                1707109200
            ],
            [
                5.27,
                1707195600
            ],
            [
                5.18,
                1707282000
            ],
            [
                5.17,
                1707368400
            ],
            [
                5.24,
                1707454800
            ],
            [
                5.46,
                1707714000
            ],
            [
                5.17,
                1707800400
            ],
            [
                5.33,
                1707886800
            ],
            [
                5.4,
                1707973200
            ],
            [
                5.28,
                1708059600
            ],
            [
                5.15,
                1708405200
            ],
            [
                5.18,
                1708491600
            ],
            [
                5.26,
                1708578000
            ],
            [
                5.26,
                1708664400
            ],
            [
                5.4,
                1708923600
            ],
            [
                5.52,
                1709010000
            ],
            [
                5.38,
                1709096400
            ],
            [
                5.36,
                1709182800
            ],
            [
                5.52,
                1709269200
            ],
            [
                5.72,
                1709528400
            ],
            [
                5.8,
                1709614800
            ],
            [
                6.12,
                1709701200
            ],
            [
                6.16,
                1709787600
            ],
            [
                6.34,
                1709874000
            ],
            [
                6.18,
                1710129600
            ],
            [
                6.22,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7417,
        "drug_name": "VRAYLAR (cariprazine)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Major depressive disorder (MDD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-19",
        "link": "https:\/\/news.abbvie.com\/article_display.cfm?article_id=12543",
        "note": "Approved December 19, 2022.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10057,
        "drug_name": "Levocarnitine Tablets USP",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Carnitine supplement",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-20",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ANIP\/news\/106101",
        "note": "Approved December 20, 2022.",
        "company_entity_id": 792,
        "company_ticker": "ANIP",
        "company_name": "ANI Pharmaceuticals Inc.",
        "company_price": "66.5400",
        "company_change": 0.41,
        "company_percent_change": 0.62,
        "company_optionable": 1,
        "company_number_of_shares": 21078986,
        "price_change_sparkline": [
            [
                55.82,
                1706677200
            ],
            [
                56.51,
                1706763600
            ],
            [
                55.42,
                1706850000
            ],
            [
                56.04,
                1707109200
            ],
            [
                56.87,
                1707195600
            ],
            [
                56.03,
                1707282000
            ],
            [
                55.91,
                1707368400
            ],
            [
                56.51,
                1707454800
            ],
            [
                57.03,
                1707714000
            ],
            [
                55.02,
                1707800400
            ],
            [
                56.1,
                1707886800
            ],
            [
                57.55,
                1707973200
            ],
            [
                59.72,
                1708059600
            ],
            [
                58.37,
                1708405200
            ],
            [
                57.63,
                1708491600
            ],
            [
                58.15,
                1708578000
            ],
            [
                59.13,
                1708664400
            ],
            [
                60.25,
                1708923600
            ],
            [
                59.94,
                1709010000
            ],
            [
                60.28,
                1709096400
            ],
            [
                67.67,
                1709182800
            ],
            [
                67.17,
                1709269200
            ],
            [
                66.42,
                1709528400
            ],
            [
                65.34,
                1709614800
            ],
            [
                65.81,
                1709701200
            ],
            [
                66.71,
                1709787600
            ],
            [
                67.42,
                1709874000
            ],
            [
                66.13,
                1710129600
            ],
            [
                66.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7712,
        "drug_name": "Lunsumio (mosunetuzumab-axgb)",
        "clinical_trial_id": "NCT02500407",
        "has_trial_insight_page": 0,
        "indication": "Follicular lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-23",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RHHBY\/news\/107745",
        "note": "Approved December 23, 2022.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4890,
        "drug_name": "ACER-001",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Urea cycle disorder (UCD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-23",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RLFTF\/news\/107971",
        "note": "Approved December 23, 2022.",
        "company_entity_id": 2030,
        "company_ticker": "ZVRA",
        "company_name": "Zevra Therapeutics Inc.",
        "company_price": "6.2400",
        "company_change": 0.11,
        "company_percent_change": 1.79,
        "company_optionable": 1,
        "company_number_of_shares": 36218164,
        "price_change_sparkline": [
            [
                5.79,
                1706677200
            ],
            [
                5.96,
                1706763600
            ],
            [
                5.78,
                1706850000
            ],
            [
                5.77,
                1707109200
            ],
            [
                5.905,
                1707195600
            ],
            [
                5.81,
                1707282000
            ],
            [
                5.95,
                1707368400
            ],
            [
                6.15,
                1707454800
            ],
            [
                6.11,
                1707714000
            ],
            [
                5.76,
                1707800400
            ],
            [
                6.14,
                1707886800
            ],
            [
                6.68,
                1707973200
            ],
            [
                6.86,
                1708059600
            ],
            [
                6.89,
                1708405200
            ],
            [
                6.78,
                1708491600
            ],
            [
                6.8,
                1708578000
            ],
            [
                6.63,
                1708664400
            ],
            [
                6.87,
                1708923600
            ],
            [
                6.95,
                1709010000
            ],
            [
                6.86,
                1709096400
            ],
            [
                6.74,
                1709182800
            ],
            [
                7.08,
                1709269200
            ],
            [
                6.22,
                1709528400
            ],
            [
                5.91,
                1709614800
            ],
            [
                6.25,
                1709701200
            ],
            [
                6.31,
                1709787600
            ],
            [
                6.1,
                1709874000
            ],
            [
                6.13,
                1710129600
            ],
            [
                6.24,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4890,
        "drug_name": "ACER-001",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Urea cycle disorder (UCD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-12-23",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RLFTF\/news\/107971",
        "note": "Approved December 23, 2022.",
        "company_entity_id": 1016,
        "company_ticker": "RLFTF",
        "company_name": "RELIEF THERAPEUTICS HLDG AG",
        "company_price": "1.6400",
        "company_change": -0.040000000000000036,
        "company_percent_change": -2.38,
        "company_optionable": 0,
        "company_number_of_shares": 11018501,
        "price_change_sparkline": [
            [
                2,
                1706677200
            ],
            [
                2,
                1706763600
            ],
            [
                1.99,
                1706850000
            ],
            [
                1.94,
                1707109200
            ],
            [
                1.93,
                1707195600
            ],
            [
                1.99,
                1707282000
            ],
            [
                1.9,
                1707368400
            ],
            [
                1.91,
                1707454800
            ],
            [
                1.8415,
                1707714000
            ],
            [
                2,
                1707800400
            ],
            [
                1.94,
                1707886800
            ],
            [
                1.94,
                1707973200
            ],
            [
                1.94,
                1708059600
            ],
            [
                1.9,
                1708405200
            ],
            [
                1.875,
                1708491600
            ],
            [
                1.82,
                1708578000
            ],
            [
                1.91,
                1708664400
            ],
            [
                1.85,
                1708923600
            ],
            [
                1.85,
                1709010000
            ],
            [
                1.8001,
                1709096400
            ],
            [
                1.75,
                1709182800
            ],
            [
                1.77,
                1709269200
            ],
            [
                1.71,
                1709528400
            ],
            [
                1.57,
                1709614800
            ],
            [
                1.71,
                1709701200
            ],
            [
                1.74,
                1709787600
            ],
            [
                1.6702,
                1709874000
            ],
            [
                1.68,
                1710129600
            ],
            [
                1.64,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6078,
        "drug_name": "TUKYSA (tucatinib)",
        "clinical_trial_id": "NCT03043313",
        "has_trial_insight_page": 1,
        "indication": "HER2 amplified metastatic colorectal cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-01-19",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SGEN\/news\/111678",
        "note": "Approved January 19, 2023.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6078,
        "drug_name": "TUKYSA (tucatinib)",
        "clinical_trial_id": "NCT03043313",
        "has_trial_insight_page": 1,
        "indication": "HER2 amplified metastatic colorectal cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-01-19",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SGEN\/news\/111678",
        "note": "Approved January 19, 2023.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2276,
        "drug_name": "BRUKINSA (zanubrutinib)",
        "clinical_trial_id": "NCT03336333",
        "has_trial_insight_page": 0,
        "indication": "First-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-01-19",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BGNE\/news\/111723",
        "note": "Approved January 19, 2023.",
        "company_entity_id": 340,
        "company_ticker": "BGNE",
        "company_name": "BeiGene Ltd.",
        "company_price": "163.7500",
        "company_change": -0.78,
        "company_percent_change": -0.47,
        "company_optionable": 1,
        "company_number_of_shares": 104577940,
        "price_change_sparkline": [
            [
                148.23,
                1706677200
            ],
            [
                149.93,
                1706763600
            ],
            [
                144.48,
                1706850000
            ],
            [
                141.81,
                1707109200
            ],
            [
                153.58,
                1707195600
            ],
            [
                147.76,
                1707282000
            ],
            [
                142.88,
                1707368400
            ],
            [
                146.98,
                1707454800
            ],
            [
                146.57,
                1707714000
            ],
            [
                141.8,
                1707800400
            ],
            [
                145.87,
                1707886800
            ],
            [
                146.07,
                1707973200
            ],
            [
                148.23,
                1708059600
            ],
            [
                148.05,
                1708405200
            ],
            [
                150.8,
                1708491600
            ],
            [
                153.78,
                1708578000
            ],
            [
                155.1,
                1708664400
            ],
            [
                160.26,
                1708923600
            ],
            [
                179.69,
                1709010000
            ],
            [
                178.48,
                1709096400
            ],
            [
                165.65,
                1709182800
            ],
            [
                165.02,
                1709269200
            ],
            [
                167.86,
                1709528400
            ],
            [
                160.42,
                1709614800
            ],
            [
                159.52,
                1709701200
            ],
            [
                162.25,
                1709787600
            ],
            [
                158.52,
                1709874000
            ],
            [
                164.53,
                1710129600
            ],
            [
                163.75,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9489,
        "drug_name": "KEYTRUDA (Pembrolizumab)",
        "clinical_trial_id": "NCT02504372",
        "has_trial_insight_page": 0,
        "indication": "Stage IB, II or IIIA non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-01-27",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/MRK\/news\/113112",
        "note": "Approved January 27, 2023.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9063,
        "drug_name": "Jaypirca (pirtobrutinib)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Relapsed\/refractory chronic lymphocytic leukemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-01-27",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/LLY\/news\/113208",
        "note": "FDA Approved on January 27, 2023.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5360,
        "drug_name": "Pirtobrutinib (LOXO-305)",
        "clinical_trial_id": "NCT03740529",
        "has_trial_insight_page": 0,
        "indication": "Mantle cell lymphoma (MCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-01-27",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/us-fda-approves-jaypircatm-pirtobrutinib-first-and-only-non",
        "note": "Approved in the US, noted January 27, 2023.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2297,
        "drug_name": "ORSERDU (elacestrant)",
        "clinical_trial_id": "NCT03778931",
        "has_trial_insight_page": 0,
        "indication": "ER+, HER2-, ESR1-mutated Breast Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-01-31",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/CNTX\/news\/113629",
        "note": "Approved January 31, 2023.",
        "company_entity_id": 977,
        "company_ticker": "CNTX",
        "company_name": "Context Therapeutics Inc.",
        "company_price": "1.1700",
        "company_change": -0.020000000000000018,
        "company_percent_change": -1.68,
        "company_optionable": 0,
        "company_number_of_shares": 15966053,
        "price_change_sparkline": [
            [
                1.02,
                1706677200
            ],
            [
                1.03,
                1706763600
            ],
            [
                1.03,
                1706850000
            ],
            [
                1.03,
                1707109200
            ],
            [
                1.02,
                1707195600
            ],
            [
                1.02,
                1707282000
            ],
            [
                0.99,
                1707368400
            ],
            [
                1.05,
                1707454800
            ],
            [
                1.14,
                1707714000
            ],
            [
                1.16,
                1707800400
            ],
            [
                1.06,
                1707886800
            ],
            [
                1.02,
                1707973200
            ],
            [
                1.0399,
                1708059600
            ],
            [
                1.146,
                1708405200
            ],
            [
                1.2,
                1708491600
            ],
            [
                1.17,
                1708578000
            ],
            [
                1.16,
                1708664400
            ],
            [
                1.1301,
                1708923600
            ],
            [
                1.19,
                1709010000
            ],
            [
                1.19,
                1709096400
            ],
            [
                1.14,
                1709182800
            ],
            [
                1.15,
                1709269200
            ],
            [
                1.14,
                1709528400
            ],
            [
                1.17,
                1709614800
            ],
            [
                1.05,
                1709701200
            ],
            [
                1.15,
                1709787600
            ],
            [
                1.2,
                1709874000
            ],
            [
                1.19,
                1710129600
            ],
            [
                1.17,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2895,
        "drug_name": "DUVROQ (Daprodustat)",
        "clinical_trial_id": "NCT03029208",
        "has_trial_insight_page": 0,
        "indication": "Anaemia in chronic kidney disease for patients on dialysis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-01",
        "link": "https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-treatment-anemia-caused-chronic-kidney-disease-adults-dialysis",
        "note": "Approved February 1, 2023.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4773,
        "drug_name": "TRODELVY (sacituzumab govitecan)",
        "clinical_trial_id": "NCT03901339",
        "has_trial_insight_page": 1,
        "indication": "HR+\/HER2- metastatic breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-03",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/GILD\/news\/114716",
        "note": "Approved February 3, 2023.",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9190,
        "drug_name": "TAKHZYRO (lanadelumab) - (SHP643-301, SPRING)",
        "clinical_trial_id": "NCT04070326",
        "has_trial_insight_page": 0,
        "indication": "Hereditary angioedema (HAE) attacks in patients 2 to <6 yrs",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-03",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/TAK\/news\/114784",
        "note": "FDA approved on February 3, 2023.",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9848,
        "drug_name": "EYLEA (aflibercept) Injection",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Retinopathy of Prematurity (ROP)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-08",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/REGN\/news\/115737",
        "note": "FDA approval on February 8, 2023.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6876,
        "drug_name": "JEMPERLI (Dostarlimab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "dMMR endometrial cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-10",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/GSK\/news\/116121",
        "note": "Full approval granted February 10, 2023.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6876,
        "drug_name": "JEMPERLI (Dostarlimab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "dMMR endometrial cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-10",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/GSK\/news\/116121",
        "note": "Full approval granted February 10, 2023.",
        "company_entity_id": 394,
        "company_ticker": "ANAB",
        "company_name": "AnaptysBio Inc.",
        "company_price": "26.0600",
        "company_change": 2.71,
        "company_percent_change": 11.61,
        "company_optionable": 1,
        "company_number_of_shares": 26575178,
        "price_change_sparkline": [
            [
                23.6,
                1706677200
            ],
            [
                24.25,
                1706763600
            ],
            [
                24.01,
                1706850000
            ],
            [
                24.07,
                1707109200
            ],
            [
                24.02,
                1707195600
            ],
            [
                23.51,
                1707282000
            ],
            [
                23.13,
                1707368400
            ],
            [
                23.01,
                1707454800
            ],
            [
                23.07,
                1707714000
            ],
            [
                22.01,
                1707800400
            ],
            [
                22.29,
                1707886800
            ],
            [
                22.76,
                1707973200
            ],
            [
                24.1,
                1708059600
            ],
            [
                23.83,
                1708405200
            ],
            [
                25.49,
                1708491600
            ],
            [
                25.28,
                1708578000
            ],
            [
                25.87,
                1708664400
            ],
            [
                26.46,
                1708923600
            ],
            [
                26.47,
                1709010000
            ],
            [
                25.81,
                1709096400
            ],
            [
                25.53,
                1709182800
            ],
            [
                25.45,
                1709269200
            ],
            [
                26.15,
                1709528400
            ],
            [
                25.33,
                1709614800
            ],
            [
                25.49,
                1709701200
            ],
            [
                24.63,
                1709787600
            ],
            [
                24.8,
                1709874000
            ],
            [
                23.35,
                1710129600
            ],
            [
                26.06,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10175,
        "drug_name": "CIBINQO (abrocitinib)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Atopic dermatitis in adolescents",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-10",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/116223",
        "note": "Approved February 10, 2023.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5043,
        "drug_name": "FILSPARI (sparsentan)",
        "clinical_trial_id": "NCT03762850",
        "has_trial_insight_page": 0,
        "indication": "IgA nephropathy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/TVTX\/news\/117633",
        "note": "FDA accelerated approval on February 17, 2023.",
        "company_entity_id": 850,
        "company_ticker": "TVTX",
        "company_name": "Travere Therapeutics Inc.",
        "company_price": "7.7500",
        "company_change": -0.24,
        "company_percent_change": -3,
        "company_optionable": 1,
        "company_number_of_shares": 76098485,
        "price_change_sparkline": [
            [
                8.93,
                1706677200
            ],
            [
                8.6,
                1706763600
            ],
            [
                8.49,
                1706850000
            ],
            [
                8.26,
                1707109200
            ],
            [
                8.67,
                1707195600
            ],
            [
                8.28,
                1707282000
            ],
            [
                8.3,
                1707368400
            ],
            [
                8.48,
                1707454800
            ],
            [
                8.86,
                1707714000
            ],
            [
                7.99,
                1707800400
            ],
            [
                8.25,
                1707886800
            ],
            [
                8.74,
                1707973200
            ],
            [
                8.2,
                1708059600
            ],
            [
                8.28,
                1708405200
            ],
            [
                7.88,
                1708491600
            ],
            [
                7.86,
                1708578000
            ],
            [
                7.94,
                1708664400
            ],
            [
                8.02,
                1708923600
            ],
            [
                8.31,
                1709010000
            ],
            [
                7.79,
                1709096400
            ],
            [
                7.56,
                1709182800
            ],
            [
                7.87,
                1709269200
            ],
            [
                8.19,
                1709528400
            ],
            [
                8.04,
                1709614800
            ],
            [
                8.61,
                1709701200
            ],
            [
                8.71,
                1709787600
            ],
            [
                8.66,
                1709874000
            ],
            [
                7.99,
                1710129600
            ],
            [
                7.75,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6607,
        "drug_name": "SYFOVRE (pegcetacoplan injection)",
        "clinical_trial_id": "NCT03525600",
        "has_trial_insight_page": 0,
        "indication": "Geographic atrophy (GA)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/APLS\/news\/117636",
        "note": "FDA Approval on February 17, 2023.",
        "company_entity_id": 465,
        "company_ticker": "APLS",
        "company_name": "Apellis Pharmaceuticals Inc.",
        "company_price": "58.5000",
        "company_change": -2.19,
        "company_percent_change": -3.61,
        "company_optionable": 1,
        "company_number_of_shares": 120581749,
        "price_change_sparkline": [
            [
                63.29,
                1706677200
            ],
            [
                62.13,
                1706763600
            ],
            [
                62.56,
                1706850000
            ],
            [
                68.16,
                1707109200
            ],
            [
                67.31,
                1707195600
            ],
            [
                66.7,
                1707282000
            ],
            [
                68.12,
                1707368400
            ],
            [
                68.56,
                1707454800
            ],
            [
                67.75,
                1707714000
            ],
            [
                66.17,
                1707800400
            ],
            [
                67.39,
                1707886800
            ],
            [
                67.58,
                1707973200
            ],
            [
                68.78,
                1708059600
            ],
            [
                67.85,
                1708405200
            ],
            [
                66.89,
                1708491600
            ],
            [
                67.59,
                1708578000
            ],
            [
                68.47,
                1708664400
            ],
            [
                71.73,
                1708923600
            ],
            [
                69.35,
                1709010000
            ],
            [
                64.05,
                1709096400
            ],
            [
                61.97,
                1709182800
            ],
            [
                63.89,
                1709269200
            ],
            [
                64.63,
                1709528400
            ],
            [
                62.47,
                1709614800
            ],
            [
                60.94,
                1709701200
            ],
            [
                62.44,
                1709787600
            ],
            [
                61.63,
                1709874000
            ],
            [
                60.69,
                1710129600
            ],
            [
                58.5,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6408,
        "drug_name": "AUSTEDO XR (deutetrabenazine)",
        "clinical_trial_id": "NCT03452943",
        "has_trial_insight_page": 1,
        "indication": "Tardive dyskinesia (TD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/TEVA\/news\/117641",
        "note": "FDA Approval on February 17, 2023.",
        "company_entity_id": 390,
        "company_ticker": "TEVA",
        "company_name": "Teva Pharmaceutical Industries Limited American Depositary Shares",
        "company_price": "13.4900",
        "company_change": 0.14,
        "company_percent_change": 1.05,
        "company_optionable": 1,
        "company_number_of_shares": 1121094011,
        "price_change_sparkline": [
            [
                12.1,
                1706677200
            ],
            [
                12.46,
                1706763600
            ],
            [
                12.28,
                1706850000
            ],
            [
                12.38,
                1707109200
            ],
            [
                12.25,
                1707195600
            ],
            [
                12.14,
                1707282000
            ],
            [
                12.09,
                1707368400
            ],
            [
                12.01,
                1707454800
            ],
            [
                12.91,
                1707714000
            ],
            [
                12.92,
                1707800400
            ],
            [
                13.17,
                1707886800
            ],
            [
                13.2,
                1707973200
            ],
            [
                13.02,
                1708059600
            ],
            [
                13.07,
                1708405200
            ],
            [
                13,
                1708491600
            ],
            [
                13.05,
                1708578000
            ],
            [
                12.89,
                1708664400
            ],
            [
                13.29,
                1708923600
            ],
            [
                13.3,
                1709010000
            ],
            [
                13.09,
                1709096400
            ],
            [
                13.15,
                1709182800
            ],
            [
                13.5,
                1709269200
            ],
            [
                13.44,
                1709528400
            ],
            [
                13.54,
                1709614800
            ],
            [
                13.53,
                1709701200
            ],
            [
                13.71,
                1709787600
            ],
            [
                13.62,
                1709874000
            ],
            [
                13.35,
                1710129600
            ],
            [
                13.49,
                1710216000
            ]
        ],
        "statuses": []
    }
]